---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-152045"
form_type: "8-K"
ticker: "SEPN"
cik: "0001984086"
company_name: "Septerna, Inc."
filed_at: "2026-04-13T23:59:59+00:00"
generated_at: "2026-05-15T06:37:33.259135+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Septerna dosed first participants in Phase 1 trial of SEP-479 oral PTH1R agonist for hypoparathyroidism

## Summary
- Phase 1 SAD/MAD trial evaluating safety, tolerability, PK/PD in up to 150 healthy volunteers.
- SEP-479 is a potent oral small molecule PTH1R agonist for hypoparathyroidism, a lifelong condition.
- Data from the trial expected in late 2026 or early 2027.
- CEO highlights potential as once-daily oral therapy, differentiating from daily injections or calcium supplements.

## SEC filing metadata
- accession: 0001193125-26-152045
- form_type: 8-K
- ticker: SEPN
- cik: 0001984086
- company_name: Septerna, Inc.
- filed_at: 2026-04-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1984086/000119312526152045/0001193125-26-152045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1984086/000119312526152045/d57504d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-152045
- JSON: https://secwatch.observer/filing/0001193125-26-152045.json
- Plain text: https://secwatch.observer/filing/0001193125-26-152045.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.